non-small cell lung cancer
Conditions
Interventions
Group 2:hypofractionated helical tomotherapy
Group 1:conventional intensity-modulated radiation therapy
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients should be diagnosed as NSCLC histologically or cytologically, driving genes negative tested by tissue and blood samples including EGFR/ALK/ROS1/MET/HER2/PIK3CA/BRAF/RET/Key; 2. Chest CT, cranial MRI, and CT/PET-CT should be performed and staging should be stage III B on the basis of UICC/AJCC 8th Edition TNM staging standard for lung cancer; 3. Aged 18-75 years old; 4. KPS scores = 70 or PS = 2; 5. The patient was initially treated, and no other anti-tumor treatment was received before enrollment. There was no pleural invasion and pleural effusion. Respiratory function compensation and heart, liver, kidney and other organs are normal; 6. patients have no history of chest radiotherapy; 7. patients can understand the situation of the study and has signed informed consent.
Exclusion criteria
Exclusion criteria: 1) patients have other malignant tumors at the same time, or the tumor-free survival time upper limit of normal value (ULN) 1.5 times, aspartate aminotransferase (AST), alanine aminotransferase (ALT) > ULN 2.5 times, serum creatinine > upper limit of normal value 1.5 times, and creatinine clearance rate < 60 ml/min; 8) patients use other experimental drugs or participation in other clinical trials simultaneous; 9) any other situation that the researcher considered patients are unsuitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year survival rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| local control rates;progrseeion-free survival;Toxic side effects; | — |
Countries
China
Contacts
Public ContactJian He
Zhongshan Hospital, Fudan University
Outcome results
None listed